MAPT and tauopathy: Indeed, our evaluation of the P2X7R antagonist Cp2 in an ex vivo model of tauopathy showed that P2X7R inhibition caused marked reductions in pathological tau inclusions, adding to a growing body of literature linking P2X7R with pathological tau changes in disease including tau misfolding (Ruan et al., 2020) and phosphorylation at specific epitopes (Carvalho et al., 2021, di Lauro et al., 2022).